Contineum Therapeutics, Inc. (CTNM)
(Delayed Data from NSDQ)
$20.77 USD
-0.23 (-1.10%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $20.60 -0.17 (-0.82%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CTNM 20.77 -0.23(-1.10%)
Will CTNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTNM based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CTNM
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics Welcomes Sarah Boyce to Board
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary